The clinical outcome of esophageal small-cell carcinoma patients is significantly worse than that of p16-positive high-grade squamous cell carcinoma patients despite the common p16/Rb1 signaling activation status; however, this has to be further confirmed in a study with a higher number of the relevant neoplasms. This evidence concerns the gene CDKN2A and squamous cell carcinoma.